← Back to Clinical Trials
Recruiting Phase 1 NCT07390747

A Trial of SHR-2173 in Healthy Volunteers

Trial Parameters

Condition Immunology
Sponsor Atridia Pty Ltd.
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 18
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2026-03-06
Completion 2026-08-30
Interventions
SHR-2173 Injection/SHR-2173 placebo

Brief Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants

Eligibility Criteria

Main inclusion criteria 1. Healthy white participants. 2. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study. 3. Male aged between 18 to 45 years of age (inclusive) 4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening. 5. Men and WOCBP must agree to take highly effective contraceptive methods Main exclusion Criteria 1. History or evidence of clinically significant disorders. 2. Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study or same class drug or any component of it. 3. Receipt of medical devices or another investigational drug within 3 months or 5 half-lives, whichever is longer prior to screening. 4. The injection site has abnormalities or is dee

Related Trials